KL-A289

The main objectives of Phase Ia: 1) To evaluate the safety and tolerability of KL-A289 injection as a monotherapy in patients with advanced solid tumors; 2) To determine the recommended dose of KL-A289 injection in Phase Ib/II studies. Secondary objectives of Phase Ia: 1) To evaluate the pharmacokinetic characteristics of KL-A289 injection in patients with advanced solid tumors; 2) To evaluate the immunogenicity of KL-A289 injection in patients with advanced solid tumors; 3) To observe the preliminary efficacy of KL-A289 injection in patients with advanced solid tumors. The main objectives of Phase Ib: 1) To evaluate the safety and tolerability of KL-A289 injection combined with albumin paclitaxel in patients with advanced solid tumors; 2) To determine the optimal dose of KL-A289 in combination therapy. The secondary objectives of Phase Ib are: 1) to evaluate the pharmacokinetic characteristics of KL-A289 injection combined with albumin-paclitaxel in patients with advanced solid tumors; 2) to evaluate the immunogenicity of KL-A289 injection combined with albumin-paclitaxel in patients with advanced solid tumors; 3) to evaluate the preliminary efficacy of KL-A289 injection combined with albumin-paclitaxel in patients with advanced solid tumors.